Needham Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY)

Needham analyst Ami Fadia reiterated a Buy rating and $52.00 price target on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY).

The analyst commented: "We hosted investor meetings with the Harmony team including Dr Jeff Dayno (CEO), Sandip Kapadia (CFO), Jeff Dierks (CCO), and Dr Kumar Budur (CMO/CSO). The main focus of the meetings was the pipeline assets particularly pitolisant's NG formulations, IH indication and ZYN002, in addition to narcolepsy market trends.

We reiterate our Buy rating as mgt seemed confident it has put Harmony in a position to evolve in a not too distant horizon from a single product story with an LOE, to one with a solid lifecycle mgt strategy, and multiple diversified assets (4 in Ph 3 by YE24) that can drive growth through at least one new product/indication launch each year over next 5 years."

For an analyst ratings summary and ratings history on Harmony Biosciences Holdings Inc. click here. For more ratings news on Harmony Biosciences Holdings Inc. click here.

Shares of Harmony Biosciences Holdings Inc. closed at $37.28 yesterday.

You May Also Be Interested In

• Tesla Nears Unveiling of Radical New ‘Flying’ Roadster - The Information
• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• Deere (DE) PT Lowered to $570 at JPMorgan Ahead of Earnings